Figure 5.

The LTX-315-induced tumoricidal activity is not markedly boosted by ICB. (a) Experimental setting. Scheduling and routing of the combination therapy with LTX-315 injected first locally and ICB injected sequentially in systemic administrations as detailed in Materials and Methods section. s.c., subcutaneous; i.p., intraperitoneal; i.t., intratumoral. (b and c) Tumor growth kinetics in the presence (right panel) or absence (left panel) of such immune checkpoint-targeting antibodies (anti-CTLA4: 100 μg/mouse or anti-PD-1 mAb: 250 μg/mouse, three injections weekly for 2 weeks) or isotype control mAbs injected after LTX-315. The Kaplan–Meier curves are depicted in the right panels gathering two experiments. In the graphs for (b and c), one representative out of two identically performed experiments comprising 6–7 mice per group is shown for the left and middle panels depicting tumor growth curves (conclusions drawn from total dataset from both replicates), and all data combined are shown in the right panels depicting Kaplan–Meier survival. Comparisons of Kaplan–Meier survival curves were performed using the log-rank Mantel–Cox test; NS, not significant